Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational study

Registos relacionados

• Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors versus single agent chemotherapy as second‐line treatment for non–small‐cell lung cancer wild‐type or unknown status for EGFR
  Por: Créquit, Perrine, et al.
  Publicado em: (2018)
• Discontinuing epidermal growth factor receptor-tyrosine kinase inhibitor during second-line chemotherapy: is the evidence strong enough?
  Por: Liang, Wenhua, et al.
  Publicado em: (2015)
• Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
  Por: Park, Sehhoon, et al.
  Publicado em: (2015)
• The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China
  Por: Xu, Jianlin, et al.
  Publicado em: (2016)
• Efficacies and adverse reactions of modified vitamin supplement programs before pemetrexed chemotherapy as a second-line treatment against epidermal growth factor receptor (EGFR) mutant wild-type lung adenocarcinoma
  Por: Zhou, Chengzhi, et al.
  Publicado em: (2015)